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ABSTRACT
Heart disease is the cause of sudden death in more than 80% of cases. Ischemic heart disease is the cause for
90% of all sudden cardiac deaths, while in the remaining 10% of cases, heart diseases have a hereditary origin
and comprise a wide spectrum of disorders that include cardiomyopathies and channelopathies. The aim of this
review is to highlight the importance of genetic counseling for patients with hereditary cardiovascular disease
and its evaluation by a multidisciplinary team.

Keywords: Heart diseases; Sudden death; Genetics; Genetic Counseling. (Source: MESH-NLM)

RESUMEN
La cardiopatía es la causa de muerte súbita en más del 80% de casos. La cardiopatía isquémica es responsable
en el 90% del total de las muertes súbitas cardiacas, mientras que en el 10% de casos restantes, las cardiopatías
tienen un origen hereditario y comprenden un amplio espectro de trastornos que incluyen a las
cardiomiopatías y las canalopatías. El objetivo de esta revisión es poner en evidencia la importancia del
asesoramiento genético de los pacientes con enfermedad cardiovascular hereditaria y su evaluación a través de
un equipo multidisciplinario.
Palabras clave: Cardiopatías; Muerte Súbita; Genética; Asesoramiento Genético. (Fuente: DeCS- BIREME)
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INTRODUCTION
Sudden, unexplained death is considered due to a
primary arrhythmic disorder when no structural heart
disease is found at autopsy and there is no prior
documentation of heart disease (1,2). In the general
population, the incidence of sudden death varies from
1/100,000 in adolescents to 1/1,000 in individuals aged
45 to 75 years (3). Is believed that channelopathies are
responsible for 10% to 15% of cases of sudden
unexplained death in young adults and children (4).
Hereditary cardiomyopathies are a genetically and
phenotypically heterogeneous group that predispose
to heart failure and sudden death, due to pathogenic
variants in genes that encode essential proteins in the
structural components of cardiomyocytes and are
functionally and morphologically classi ed by their
characteristics in: hypertrophic cardiomyopathy,
c a r d i o m y o p a t h y
d i l a t e d
cardiomyopathy/arrhythmogenic right ventricular
dysplasia, cardiomyopathy due to noncompaction of
the ventricle, and restrictive cardiomyopathy (5).
Channelopathies are a group of hereditary syndromes
of cardiac arrhythmia, with variable clinical expression,
including Brugada syndrome, catecholaminergic
polymorphic ventricular tachycardia, long QT
syndrome, short QT syndrome, and early repolarization

Figure 1. Work

syndrome (6). These channelopathies arise from defects
in macromolecular complexes of ion channels or
proteins critical for the intracellular handling of calcium,
sodium, and/or potassium. Patients with
channelopathy usually have a structurally normal heart
but are predisposed to syncope/arrhythmic seizures
and sudden cardiac death (7).
From the discovery of genes associated with hereditary
cardiovascular disease of monogenic origin in the early
1990s to the present day, where studies of genetic
panels or complete exomes (6) are carried out in patients
with suspected hereditary heart disease, genetic
studies meet an important role in supporting the
diagnosis of a primary arrhythmia disorder. In addition,
they provide prognostic information and allow the
evaluation to be extended to asymptomatic rstdegree relatives at risk. Genetic studies are used in
clinical practice at the time of risk strati cation and
patient management, based on precision medicine,
focused on genomic medicine (Figure 1) (8).
The aim of this review is to highlight the importance of
genetic counseling for patients with hereditary
cardiovascular disease and its evaluation by a
multidisciplinary team.

owchart in patients with suspected congenital heart disease.
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Hypertrophic cardiomyopathy

cardiomyocytes (15). Furthermore, some data suggest

Hypertrophic cardiomyopathy (HCM) is characterized

that left ventricular hypertrophy may be caused by

by left ventricular hypertrophy in the absence of an

alterations in the transforming growth factor B and

underlying systemic condition or other cardiac disease,

CaMKII Mef2 signaling pathways (16).

such as valvular heart disease or hypertension. It is
estimated to have a prevalence of 1 in 500 in the general
population (9). HCM is the most common inherited type
of heart condition and the leading cause of sudden
death in young adults and competitive athletes in the
United States (10). Although the age of onset of HCM can
range from infancy to old age, manifestations, in those
carrying a pathogenic variant, usually do not appear
before adolescence (10). HCM is primarily inherited in an

According to the genetic etiology of HCM, pathogenic
variants have been described in several genes encoding
sarcomeric proteins, with the majority (80%) being in
the MYH7 and MYBPC3 genes (17). (Table 1) Pathogenic
variants in genes encoding a sarcomere component are
found in approximately 50% - 60% of probands (adults
and children) with a family history of HCM, and in
approximately 20% -30% of probands without a family
history of HCM (18).

autosomal dominant pattern, with reduced penetrance
and clinical variability. Clinical manifestations vary from

Approximately 3% - 5% of aﬀected individuals have

being completely asymptomatic to progressive heart

biallelic variants in 1 gene or heterozygous variants in

failure and sudden death caused by mechanical or

more than 1 gene (19). Recently, the spectrum of genes

electrical defects.

associated with HCM has expanded to non-sarcomeric
genes and includes genes encoding Z-disk proteins and

HCM is de ned by the presence of unexplained left

proteins located in the sarcoplasmic reticulum and

ventricular hypertrophy with a maximum wall thickness

plasma membrane. However, variants in these genes

(11)

≥15 mm in adults or a Z score > 3 in children . If there is

are rare.

a family history of HCM, or if genetic testing con rms
that a family member has inherited any pathogenic

Variants in the MYH7 gene generally lead to signi cant

variant, LV maximum wall thickness ≥ 13 mm will

left ventricular hypertrophy in the second decade of life

support the diagnosis. Altered left ventricular

and are believed to be associated with an increased risk

relaxation, may be identi ed in individuals possessing a

of heart failure and sudden cardiac death (20). In contrast,

pathogenic variant in a gene encoding a sarcomere
component (nonsyndromic HCM) who have normal left
ventricular wall thickness (12) suggesting that diastolic
dysfunction is an early phenotype of HCM rather than a
secondary consequence of left ventricular hypertrophy.
Although left ventricular hypertrophy and a clinical
diagnosis of HCM are often evident during adolescence,
around the onset of puberty, or during adulthood, the
onset may be earlier (in infancy and childhood) (13).

pathogenic variants in MYBPC3 are thought to be
associated with older age at diagnosis (18) although they
have also been identi ed in a signi cant proportion of
patients with childhood-onset left ventricular
hypertrophy (19).
The diﬀerential diagnosis of HCM includes various
syndromes that usually manifest with multiorgan
involvement but may also present with isolated or
predominant left ventricular hypertrophy. These
syndromes include metabolic depot cardiomyopathies

HCM is frequently described as a disease of the

such as Danon disease (LAMP2 gene), Wolﬀ-Parkinson-

sarcomere, and pathogenic variants have been

White syndrome (PRKAG2 gene) (21), Fabry disease which

detected in almost all sarcomeric proteins (14). Molecular

is a lysosomal storage disorder (GLA gene) (22) as well as

mechanisms include increased actin-activated ATPase

syndromic (with other systemic involvement) (Table 2)

activity, disruption of

and non-syndromic (without other systemic

and altered I

actin-myosin

ntracellular

interaction,

calcium signaling in

involvement) disorders.
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Table 1. Genes associated with hypertrophic cardiomyopathy.
Gene

Inheritanc
e

% of HCM caused by
pathogenic variant in t his
gene

MYBPC
3

AD

50%

MYH7

AD

33%

TNNI3

AD

5%

TNNT2

AD

4%

ACTC1
MYL2

AD
AD
AD
AR
AD
AD
AR
AD
AD
AD
AD
AD
AD

<3%
<3%

MYL3

Allelic disorders
DCM
Myosin Deposit Myopathy
Cardiomyopathy due to
noncompaction of the ventricle
DCM
Restrictive cardiomyopathy
DCM
Cardiomyopathy due to
noncompacted ventricle
Familial restrictive cardiomyopathy
DCM

<3%

OMIM (Online
Mendelian Inherited in
Man)
600958
160760
191044

191045
102540
160781
160790

<3%
<3%
Rare
<1%
<1%
<1%
Rare
<1%
<1%

DCM
DCM

191010
172405
617608
102573
600824
191040
605267
605602
613121

TPM1
PLN
ALPK3
ACTN2
CSRP3
TNNC1
JPH2
MYOZ2
NEXN
ANKRD
1
CALR3
KLF10
MYH6
MYLK2
MYOM1

AD

Rare

AD
AD
AD
Digenic
AD

Rare
Rare
Rare
Rare
Rare

DCM

611414
601878
160710
606566
603508

MYPN

AD

Rare

DCM
Nemaline myopathy

608517

OBSCN
PDLIM3

AD
AD

Rare
Rare

RYR2

AD

Rare

TCAP
TRIM63

AD
AD

Rare
Rare

TTN

AD

Rare

VCL

AD

Rare

DCM
DCM
DCM

DCM

608616
605889
Arrhythmogenic cardiomyopathy
of the right ventricle
Catecholaminergic polymorphic
ventricular tachycardia
DCM
DCM
Hereditary myopathy with early
respiratory failure
Salih distal myopathy
Distal myopathy Udd
DCM

180902
604488
606131

613765

193065

AD: autosomal dominant; AR: Aautosomal recessive; DCM: Dilated cardiomyopathy.
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Table 2. Syndromic hypertrophic cardiomyopathy.
Disorder

Danon's disease

Fabry disease

Gene(s)

Heritag
e

LAMP2

XL

GLA

XL

Other clinical features (non
●
●
●

●
●
●
●
●
●

●
●
●
●

Facial characteris cs
Short stature
Variable developmental delay
Broad, winged neck

●
●
●
●
●

Friedreich ataxia

FXN

AR

Glycogen storage disease of the heart,
congenital lethal

PRKAG2

AD

●
●
●
●
●
●

Hereditary transthyre n amyloidosis

Pompe disease

Rasopathies:
Noonan syndrome
Cardiofasciocutaneous syndrome
● Costello syndrome
Noonan syndrome with mul ple
len gines

●

●
●

TTR

GAA
BRAF
HRAS
KRAS
LZTR1
MAP2K1
MAP2K2
NRAS
PTPN11
RAF1
RASA2
RRAS
RIT1
SOS1
SOS2

AD

AR

AD

-cardiac)

Myopathy
Retinal dystrophy
Periodic pain crises in the
extremities
Angiokeratomas
Hypohidrosis
Ocular abnormalities
Proteinuria and deterioration of
renal function
Ataxia, slowly progressive before 25
years of age
Dysarthria
Muscle weakness
Neonatal hypoglycemia
Vacuolar myopathy
Facial dysmorphia and/or
macroglossia
Slow progressive peripheral sensorymotor neuropathy and autonomic
neuropathy
Vitreous opacity
CNS amyloidosis
Poor nutri on
Macroglossia
Motor delay / muscle weakness
Respiratory distress

AD: autosomal dominant; AR: Aautosomal recessive; XL: X-linked

Dilated cardiomyopathy

greater genetic heterogeneity (more than 40 genes

Dilated cardiomyopathy (DCM) is de ned by left
ventricular dilatation and systolic dysfunction, and is
the most common indication for cardiac
transplantation in the United States (23). The spectrum of
clinical manifestations includes hear t failure,
thromboembolism, and sudden death. The estimated
prevalence of idiopathic type DCM is 1 in 2500
individuals. The percentage of idiopathic CMD that have
a genetic etiology is estimated to be between 30% and
50% depending on the presence of family history (23). The
age of onset can range from childhood to late
adulthood, although most patients are diagnosed
between 20 and 50 years of age (24). Compared to HCM,
which is primarily a sarcomere disease, DCM presents

described to date) (25).
DCM is mainly inherited in an autosomal dominant
pattern, however, X-linked inheritance has also been
described (26). Due to the locus and allelic heterogeneity
of DCM, gene panels are the most frequently used
genetic tests. It is estimated that pathogenic variants
can be identi ed in 17% to 30% of individuals with DCM
when multigene panel analysis of up to 20 genes is
performed (27). Pathogenic variants in the LMNA and
SCN5 genes are clearly associated with DCM and
conduction system disease (28).
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Pathogenic variants in the TTN gene are identi ed in up
to 25% of familial cases and 18% of sporadic cases of
DCM (29). (Table 3). Individuals with CMD in whom the
cause has been determined not to be acquired

(secondary) or syndromic (with other systemic
involvement) (Table 4), have nonsyndromic DCM
(without other systemic involvement).

Tabla 3. Genes associated with dilated cardiomyopathy.
Gene

Heritage

ACTC1
ACTN2
ANKRD1

<1%
<1%
2.2%

% of HCM caused by
pathogenic variant in
this gene
AD
AD
AD

BAG3

2.5%

AD

CSRP3
DES

<1%
<1%

AD
AD

DMD

?

XL

DSG2

AD

EYA4
LDB3

?
1%

AD
AD

LMNA

6%

AD

MYBPC3
MYH6
MYH7

2%-4%
3%-4%
4.2%

AD
AD
AD

NEXN
PLN

<1%
?

AD
AD

PSEN1
PSEN2

<1%
<1%

AD
AD

RBM20

1.9%

AD

SCN5A

2%-4%

AD
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Allelic disorders

Arrhythmia and
neuromuscular
involvement
Neuromuscular
involvement
Possible right
ventricular
involvement
Deafness

Arrhythmia and
conduc on system
disease

OMIM (Online Mendelian
Inherited in Man)
Family HCM
Family HCM

102540
102573
609599

Progressive Myoﬁbrillar
Myopathy
Family HCM
Myoﬁbrillar Myopathy

603883,
PS601419
600824
125660,
PS601419

Dystrophinopathies

300377
125671

Non-syndromic deafness
Myoﬁbrillar myopathy
Par al lipodystrophy
Charcot Marie Tooth 2B1
Emery-Dreifuss muscular
dystrophy
Hutchinson-Gilford Progeria
Syndrome
Atypical Werner's syndrome
LMNA-related muscular disease
Family HCM
Family HCM
Laing's distal myopathy
Family HCM
Deposit myopathy (MYH7)
Noncompac on ventricular
Cardiomyopathy
Family HCM

Arrhythmia and
conduc on system
disease
Early-onset Alzheimer's disease
Early- and late-onset Alzheimer's
disease
Arrhythmia and
conduc on system
disease
Arrhythmia and
conduc on system
disease

Gene

603550
605906,
PS601419
150330

600958
160710
160760

613121
172405

104311
600759
613171

Long QT syndrome type 3
Brugada Syndrome
Idiopathic ventricular ﬁbrilla on
Sick sinus syndrome
Cardiac conduc on system
disease

600163

6
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SGCD
TAZ

<1%
?

AD
XL

TCAP
TMPO

1%
1.1%

AD
AD

TNNC1
TNNI3

AD
AD

TNNT2

<1%-1.3%
1.3% (AD)
<1% (AR)
2.9%

TPM1

<1%-1.9%

AD

Childhood
presenta ons

AD

Delta sarcoglycanopathy
Barth's syndrome
Endocardial ﬁbroelastosis type 2
Familial noncompac on
ventricular cardiomyopathy
Family HCM

601411
300394

Family HCM
Family HCM
Restric ve cardiomyopathy
Family HCM
Noncompac on ventricular
cardiomyopathy
Family restric ve cardiomyopathy
related to TNNT2
Family HCM

191040
191044

604488
188380

191045

191010

Table 4. Syndromic dilated cardiomyopathy.
Disorder

Gene(s)

Heritage

Barth syndrome

TAZ

XL

Carvajal syndrome

DSP

AR

Other clinical features (non-cardiac)

●
●
●
●
●

Neutropenia
Muscle weakness
Delayed development
Wooly hair
Palmoplantar keratoderma

In males:
Duchenne / Becker
muscular dystrophy

DMD

XL

Emery-Dreifuss
muscular dystrophy

EMD
FHL1
LMNA

XL
AD
AR

Hereditary
hemochromatosis

HFE

AR

Laing's distal
myopathy

MYH7

AD

Limb-girdle muscular
dystrophy IB

LMNA

AD

Mitochondrial DCM

DNAmt

Mat

●
●
●
●
●
●
●
●
●
●
●

Observa ons

Muscle weakness
Elevated serum CK levels
Loss of ambula on in childhood
Joint contractures
Elevated serum CK levels
Muscle weakness in childhood/early
adulthood
Cirrhosis
Diabetes
Hypermelano c pigmenta on
Increased serum iron and ferri n
levels.
Facial weakness
Weakness (childhood onset) of
ankles, big toes, ﬁnger extensors
and neck ﬂexors.

Proximal weakness of the lower extremi es

Heterozygous females
may present isolated
DCM.
Conduc on system
diseases and/or
arrhythmias are frequent.
Non-dilated and/or
inﬁltra ve
cardiomyopathy is more
frequent than DCM.

Diseases of the
conduc on system and/or
arrhythmias are frequent.

Complex phenotypes including:
Focal segmental glomerulosclerosis.
Kearns-Sayre syndrome

AD: autosomal dominant; AR: Aautosomal recessive; XL: X-linked; mtDNA: Mitochondrial DNA; Mat: Maternal inheritance

Pág. 847

Published by INICIB-URP, 2021

7

Revista de la Facultad de Medicina Humana, Vol. 22 [2021], Iss. 4, Art. 20

Genetic testing should be oﬀered to all individuals of
(30)

ARVC is primarily described as a disease of the

any age with non-ischemic DCM , including those with

desmosome, a multiprotein complex that forms cell-to-

peripartum or pregnancy-associated

cell junctions and binds intermediate

cardiomyopathy (31). The purpose of establishing a

adjacent cells, thereby establishing a functional

molecular diagnosis of DCM is to inform the risk

intercellular network. Desmosomes are especially

assessment of the patient's relatives.

prevalent in tissues that are subjected to mechanical

Pathogenic, probably pathogenic and variants of

why the phenotypic spectrum of ARVC encompasses

laments of

stress, such as cardiac muscle and skin, which explains
uncertain signi cance in more than 30 genes have been

cardiac and cutaneous manifestations. Molecular

reported in 40%-50% of individuals with familial DCM

mechanisms of ARVC include impaired cell-cell

(when there are more than two aﬀected rst-degree

adhesion and defective transmission of contractile

relatives) (32) or in isolated cases (in only one family

force (39).

(33)

member) . The detection rate of pathogenic and
probably pathogenic variants is approximately 27% (34).
Currently, genetic studies through multigene panels
have allowed the simultaneous and parallel analysis of
all DCM-related genes. Given the complexity of
interpreting the results of genetic testing and their
implications for follow-up and management, these
cases should be discussed in a multidisciplinary manner
that includes the corresponding genetic counseling (35).
Screening in asymptomatic rst-degree relatives of an
individual with DCM may allow for early detection,

Most of the pathogenic variants in ARVC are present in
the JUP, DSP, DSC2, DSG2 and PKP2 genes (40). In addition,
homozygous or compound heterozygous variants in
the DSP and JUP genes have been described in patients
with DCM or ARVC (41). Some non-desmosomal genes
have also been described, including the TMEM43
gene (42). Analysis of the coding sequence of desmosomal
genes can identify a pathogenic variant in up to 50% of
individuals with ARVC, with 40% of cases being due to a
variant in the PKK2 gene (40).

immediate initiation of treatment, and improved longterm outcomes (36). Clari cation of the genetic status of

Cardiomyopathy due to non-compaction ventricle

rst-degree family members of an individual with DCM

Isolated non-compaction ventricular cardiomyopathy

may inform the indication and frequency of appropriate

(NVC) is characterized by a highly trabeculated

cardiovascular evaluations.

appearance of the LV myocardium. It is believed that the
arrest of myocardial compaction during the

rst

Arrhythmogenic right ventricular cardiomyopathy

trimester of embryonic development is the cause,

Arrhythmogenic right ventricular cardiomyopathy

however, several authors have proposed that it may be

(ARVC) is de ned by myocyte loss and

brofatty

an acquired process based on observations of cases of

in ltration in the myocardium, which is associated with

patients who develop NVC after having normal

increased susceptibility to arrhythmias and sudden

echocardiographic ndings. previous (43).

death, and accounts for a signi cant portion of sudden
deaths in athletes and young adults (37). ARVC is typically

The actual prevalence of NVC is unknown, however,

inherited under an autosomal dominant pattern with

there are several reports indicating that it ranges from

reduced penetrance and variable expressivity, aﬀecting

0.014% to 1.3%.(43) Patients with NVC tend to have

(38)

males more frequently than females .

early-onset disease, with clinical expression ranging
from asymptomatic to progressively impaired cardiac

In young adults, 80% of cases are diagnosed before the

func tion, ventricular hyper trophy, increased

age of 40 years. De nitive diagnosis can be challenging

thromboembolic events and sudden death (44). The left

for the clinician due to phenotypic overlap with other

ventricle is usually aﬀected, but 50% of patients have

genetic and acquired cardiomyopathies.

right ventricular involvement in addition (45).

Pág. 848
https://inicib.urp.edu.pe/rfmh/vol22/iss4/20
DOI: https://doi.org/10.25176/RFMH.v22i4.5098

8

Castro-Mujica et al.: Genetic studies to determine the risk of non-ischemic sudden deat

The World Health Organization lists NVC as an
unclassi ed cardiomyopathy

(46)

as does the European

(47)

LQTS can be caused by both genetic factors and
acquired factors. Congenital LQTS is an inherited

Society of Cardiology . On the other hand, the

disease caused by diﬀerent mutations in the genes that

American Heart Association classi ed CNVC as a

code for Na+ or K+ transmembrane ion channel

primary genetic cardiomyopathy in 2006 (48). Variants

proteins (22). There are two types of classic congenital

have been described in known genes associated with

LQTS: Jervell and Lange-Nielson syndrome (long QT

DCM and HCM that encode components of the

syndrome and deafness) and Romano Ward syndrome

sarcomere (ACTC1, MYH7, MYBPC3 and TNT2)
disc (LDB3)

(50)

(49)

, the Z-

(isolated QT interval prolongation). Both are related to

(51)

episodes of sudden cardiac death due to ventricular

, the nuclear lamina (LMNA) , the
(52)

dystrophin-associated glycoprotein complex (DTNA) ,
(53)

as well as the Bart syndrome gene (TAZ) .

brillation or Torsades de Pointes arrhythmias that
ultimately lead to death (61). In total, up to 15 types of
LQTS have been identi ed, which cause a slowdown in

Restrictive cardiomyopathy

the inactivation process of the depolarizing current of

Restrictive cardiomyopathy (RCM) is characterized by

sodium into the cell and retard the repolarizing current

increased stiﬀness of the ventricular chambers,

of potassium out of the cell. All of the above causes an

although ventricular wall thickness and systolic

increase in depolarization and dispersion of

function are generally within normal limits. The majority

repolarization (62).

of patients with RCM develop heart failure, leading to
The mortality rate of untreated patients with LQTS is

early death (54).

estimated to be approximately 1% - 2% per year. The
Several reports suggest that there is a clinical overlap

incidence of sudden cardiac death varies from family to

. Recent studies have

family depending on the speci c genotype. The

identi ed pathogenic variants in sarcomeric protein-

international LQTS registry reports that the frequency of

coding genes, including TNNI3, TNNT2, MYH7, and

cardiac events was signi cantly higher in individuals

between RCM and HCM

(55)

ACTC1 . In addition, nonsense variants in the desmin

with LQTS1 (63%) or LQTS2 (46%) compared with

gene (DES) have been identi ed in several families with

patients with LQTS3 (18%) (63). In addition, the mean

desmin-related myopathy, which may present with

range QTc was signi cantly longer in the LQTS3 group

(56)

. The European Heart Rhythm Association

(510 ± 48 ms) compared to the LQTS1 (490 ± 43 ms) or

Guidelines recommend targeted genetic testing for the

LQTS2 (495 ± 43) groups (64). In addition, it was found that

speci c genetic variant in all at-risk family members

although cumulative mortality up to age 40 was similar

following identi cation of a pathogenic variant in the

in the groups of the three genotypes, the probability of

CMR

(57)

dying during a cardiac event was higher in LQTS3

(58)

patient testing .

individuals (20%) than in LQTS1 and LQTS2 individuals
Long QT syndrome (LQTS)

(4% for each group) (64). From the genetic point of view,

Long QT syndrome is characterized by excessive

LQTS is a heterogeneous condition, which has an

prolongation of ventricular repolarization associated

incomplete penetrance (40%) (65).

with an increased risk of ventricular tachyarrhythmias,
syncope, or sudden death in patients with a

Although mutations aﬀecting genes KCNQ1 (LQTS1),

. The estimated

KCNH2 (LQTS2), and SCN5A (LQTS3) are responsible for

prevalence ranges between 1:2,500 and 1:5,000.

more than 90% of genetically de ned cases of LQTS (66).

However, due to the probability that 2/3 of the patients

(Table 5), they have also been described less common

are underdiagnosed and that approximately between

forms (<1% of cases) with heterogeneous molecular

10% and 35% of them have a normal QTc-corrected

etiologies (AKAP9, ANK2, CACNA1C, CALM1, CALM2,

interval (QTc), it is possible that the real prevalence is

CAV3, KCNE1, KCNE2, KCNJ2, KCNJ5, SCN4B, SNTA1)

morphologically intact heart

higher

(21,22,60)

.

(2,59)

ultimately expressed as QT interval prolongation and
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increased risk of fatal ventricular arrhythmias. There is
signi cant variability in the rates of LQTS events, even
within the same genetic subgroup, which leads to a
diversity of clinical and genetic variables that confer
(according to their combination of presentation in each
patient) diﬀerent types of risk for each patient.
individual (67,68). Also, it was determined that the
appearance of arrhythmic events during childhood is an
important predictor of risk since it has been reported
that people who have their rst event in this period have
a very high risk to present future events (69).

LQTS prognosis is also related to the underlying genetic
abnormality. Some data from the International LQTS
Registry show that the frequency of clinical events,
before the start of treatment, from birth to the age of 40
years, was signi cantly higher in patients with LQTS2
(46%) and LQTS3 (42%) compared with those with
LQTS1 (30%) (68). A higher lethality and lower response to
treatment have also been reported for events related to
LQTS3 than with other subtypes (69). Pathogenic variants
that result in amino acid changes in regions Speci c ion
channel pathways also confer an increased risk of
arrhythmia (2).

Table 5. Genes associated with long qt syndrome.
Gene

LQTS
phenotype

% of LQTS a ributed to
pathogenic variants in this gene

Propor on of pathogenic variants detected by given
methodology
Sequencing analysis

Dele on/duplica on analysis

KCNH2

LQTS type 2

25%-30%

97%-98%

2%-3%

KCNQ1

LQTS type 1

30%-35%

97%-98%

2%-3%

SCN5A

LQTS type 3

5%-10%

All variants reported to date

None reported

The con rmatory diagnosis of LQTS will be made in
patients who meet the clinical criteria for disease and
the presence of a pathogenic variant in any of the genes
involved identi ed by genetic testing; through, analysis

respectively (71). Although. syncopal events are more
common in type 1 LQTS phenotype (63%), followed by
type 2 LQTS phenotype (46%) and type 3 LQTS
phenotype (18%), the incidence of death is similar in all
three (71).

of speci c genes, multigene panels and/or more
complete exome or genomic tests. The sequencing
analysis of a speci c gene will be carried out in the event
that the familiar pathogenic variant is known (70).
Of people who die from complications of LQTS, death is
the rst sign of the disorder in an estimated 10% to 15%.

For the type 1 LQTS phenotype (a speci c pathogenic
variant), a severe increase in mortality was observed
during childhood (ages 1-19 years), for the type 2
phenotype, an increase in mortality was observed
between ages 15 and 39 years, and in the type 3
phenotype, an increase in mortality was observed
between the ages of 15 and 19 years (73).

Long QT syndrome registry studies including patients,
individuals with a pathogenic variant (mostly treated),
and also relatives who died suddenly show cumulative
mortality before the age of 40 years of 6%-8% in type 1
LQTS, type 2, and type 3 phenotypes

(71,72)

. In individuals

between the ages of 0 and 18 years, those with a type 1,
type 2, or type 3 LQTS phenotype had cumulative
mortality of 2%, 3%, and 7%, respectively (71). From ages
19 to 40, mortality rates were 5%, 7%, and 5%,
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Some types of LQTS are associated with a phenotype
that extends beyond cardiac arrhythmia (72) :
- Andersen-Tawil syndrome (LQTS type 7) is associated
with a prolonged QT interval, muscle weakness, and
facial dysmorphism.
- Timothy syndrome (LQTS type 8) is characterized by a
prolonged QT interval and neurodevelopmental
features of the hands/feet, facial.
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- Jervell and Lange-Nielson syndrome (JLNS), an LQTS
disorder associated with pathogenic biallelic variants
KCNQ1 or KCNE1, is associated with profound
sensorineural hearing loss.
It is important to note that LQTS associated with biallelic
or heterozygous pathogenic variants in two diﬀerent
genes (digenic pathogenic variants) is generally
associated with a more severe phenotype with a longer
QT interval and a higher incidence of cardiac events (74).
To date Speci c genotype-phenotype correlations have
not been established. Additionally, LQTS exhibits
reduced penetrance relative to ECG ndings.
Approximately 25% of people with a pathogenic variant
have a normal QT interval (<440 ms) on baseline ECG. In
a study conducted by Priori, it was determined that the
percentage of genetically aﬀected individuals with the
presence of a normal QTc was higher in the LQTS type 1
group (36%) than in the LQTS type 2 (19%) or type 3
(10%) group. %) (75). In addition, the penetrance of
symptoms is also reduced, at least 37% of patients with
type 1 LQTS phenotype, 54% with type 2 phenotype and
82% with type 3 phenotype remain asymptomatic (76).

atrial and ventricular arrhythmias, and a predisposition
to sudden cardiac death (77,78). Because it is a rare
condition, data on its prevalence and demographics are
still limited.
Most patients with SQTS have a family history of sudden
death and/or AF. The age at the onset of clinical
manifestations may be childhood, which is why it has
been classi ed as a possible cause of sudden infant
death. The severity of the clinical manifestations of short
QT syndrome is highly variable, from asymptomatic to
AF, recurrent syncope, and sudden death (79).
Genetic analyzes reveal that SQTS is a genetically
heterogeneous disease (Table 6) with pathogenic gainof-function variants in the KCNH2 gene, giving rise to
short QT syndrome type 1 (SQTC1), in the KCNQ1 gene
associated with short QT syndrome type 2 (SQTS2), in
the KCNJ2 gene associated with short QT syndrome
type 3 (SQTS3) and loss-of-function variants with a
Brugada syndrome phenotype in the CACNA1C gene,
giving rise to short QT syndrome type 4 (SQTS4) and in

Short QT syndrome (SQTS)
Short QT syndrome (SQTS) is an autosomal dominant
inherited channelopathy characterized primarily by a
shorter-than-normal QT interval on EKG (<350 ms),

the CACNB2 gene, giving rise to short QT syndrome type
5 (SQTS5) (80). Data from a cohort of patients suggest that
carriers of KCNH2 mutations may have a shorter QT
interval (81).

Table 6. Genes associated with short qt syndrome.
Subtype

Mode of
inheritance

Gene

Net eﬀect of mutation
Ikr function gain
Function gain of Iks
Function gain of Ik1
Loss of function of Ica
Loss of function of ICa

Like most inherited channelopathies, SQTC is
genetically heterogeneous with an autosomal
dominant mode of inheritance. Both gain-of-function
mutations in potassium channels and loss-of-function
mutations in calcium channels have been implicated in
the genetic basis of the disease (81. To the present day,

pathogenic variants have been identi ed in ve
diﬀerent genes that are responsible for subtypes of the
syndrome ranging from SQTC1 to SQTC5 (2). The
diagnosis of SQTS should be considered in patients who
mainly have an EKG study that reveals a short QT
interval, family history of SQTS, or sudden death before
40 years old (82).
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Brugada syndrome (BrS)

quantitative reduction or a qualitative dysfunction of

Brugada syndrome (BrS), also known as right bundle

the channels (85,86). In this subtype of BrS (Br1), the clinical

branch block syndrome, persistent ST-segment

ndings that correlate with a pathogenic variant are a

elevation, and sudden death syndrome, is a hereditary

longer PR interval on resting ECG and an exaggerated

channelopathy rst described in 1992, which is mainly

increase in QRS duration with ventricular channel

characterized by a characteristic electrocardiographic

blocking agents. sodium (87). Genetic background seems

pattern in the right precordial leads and the

to play a very important role in the phenotypic

predisposition to present ventricular arrhythmias and

expression of the disease in the ECG (88).

sudden cardiac death (83). It is considered the cause of 4%
- 12% of all sudden deaths and up to 20% of sudden

Pathogenic variants in other genes have also been

deaths that occur in patients with structurally normal

associated, less frequently, with the occurrence of BrS.
Variants in the GPD1L (Br2) gene were initially identi ed

(84)

hearts .

by linkage analysis in a large family (89) and later in victims
It has been determined that BrS has a prevalence of 5 in

of sudden infant death syndrome (90). On the other hand,

every 10,000 inhabitants, although this gure possibly

in a group of patients with BrS associated with short QT

underestimates the real prevalence given that patients

intervals, candidate gene screening revealed loss-of-

may present silent forms of the disease . In certain

function mutations in CACNA1C resulting in Brugada

populations of Southeast Asia, such as the Philippines,

syndrome type 3 (BrS3) and in CACNB2 resulting in

Japan and Thailand are considered an endemic health

Brugada syndrome type 4 (BrS4) (90). Other genes related

problem (85).

to BrS less frequent (<1% of cases) are: SCN1B, KCNE3,

(85)

SCN3B, HCN4 (91).
Although BrS is transmitted under an autosomal
dominant pattern of inheritance (84), the estimated

In patients with a positive Brugada pattern on ECG,

clinical penetrance based on the analysis of individuals

genetic screening targeting the SCN5A gene may be

carrying pathogenic variants of the sodium channel is

helpful. In the event that a pathogenic variant is found, it

(84)

16% . Despite the fact that to date several genes have

is recommended to carry out speci c mutation tests in

been identi ed that cause BrS, in most cases (~ 65%) no

rst-degree relatives (82). The nding of a genetic variant

genetic mutation is identi ed (2).

is an indicator of the potential development of the
clinical phenotype of the disease. These patients should

In 1998, the rst pathogenic variants related to BrS were

be carefully monitored in order to identify the

identi ed in the SCN5A gene (locus 3p21), which codes

spontaneous appearance of the Brugada type 1 pattern,

(86)

for the cardiac sodium channel . The selection of said

the appearance of clinical symptoms, or a combination

gene in a small number of families and individuals with

of both (2).

idiopathic ventricular

brillation and an EKG

characteristic of BrS revealed missense, frameshift, and

Catecholaminergic polymorphic ventricular

splicing variants. Pathogenic loss-of-function variants in

tachycardia (CPVT)

SCN5A were found in up to 28% of patients with positive

Catecholaminergic polymorphic ventricular

(86)

genetic tests .

tachycardia (CPVT) is a highly lethal form of the
hereditary arrhythmogenic disease characterized

Currently, more than 100 diﬀerent pathogenic variants

mainly by the occurrence of polymorphic ventricular

responsible for BrS have been described in the SCN5A

arrhythmias in the presence of catecholamine

gene, the eﬀect of which in all cases is the reduction of

production (through physical exercise and/or stress)

sodium transmembrane currents (Ina), due to a

and in the absence of structural heart disease (92).
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CPVT is an infrequent entity (1: 10,000 inhabitants), but
very important, due to the high risk of sudden death
that it entails (92). This gure could be underreported
because the fact of not identifying any genetic mutation
could lead to diagnoses such as idiopathic ventricular
brillation (93). In the absence of adequate treatment, it is
estimated that up to 50% of aﬀected patients will die
suddenly before the age of 20 (112). The average age of
onset of the disease ranges from 6 and 10 years,
although sporadic cases around 30 years have also been
reported (93).
CPVT should be suspected in all young patients,
especially children or adolescents, who present
syncope related to physical exercise or emotional stress,
who do not have structural heart disease and whose
electrocardiogram shows a normal QT interval (93). In the
year 2001 Priori and Lahat discovered the genetic cause
of the disease by identifying two variants (95), one
inherited under an autosomal dominant pattern
associated with variants in the gene that codes for the
cardiac ryanodine receptor (RyR2) and another
inherited under an autosomal dominant pattern.
autosomal recessive associated with homozygous
mutations in the gene encoding the cardiac isoform of
calsequestrin (CASQ2). Today it is possible to con rm
the diagnosis by performing diﬀerent genetic tests on
the genes known to be associated with the disease (96,97).
Subsequently, mutations in the calsequestrin 2 (CASQ2)
gene were identi ed in a patient with an autosomal
recessive inheritance pattern of CPVT (CPVT2) (95). This
was the second gene related to CPVT. Calsequestrin 2 is
a crucial protein in the regulation of intracellular Ca2+. It
constitutes the largest reservoir of this ion in the
sarcoplasmic reticulum and also modulates its release
through RyR2. When the capacity of calsequestrin 2 to
store Ca2+ decreases, the concentrations of this free ion
in the intercellular space increase, a fact that will
determine the premature activation of RyR2 that will
release more Ca2+ ions during systole (96).
Approximately 30% - 40% of patients with CPVT have a
family history of sudden death; a fact that supports the
genetic origin of this disease (93). To date, 130 mutations
in RyR2 have been characterized, representing between
50-60% of all those identi ed in CPVT (96). These exhibit a
pattern of autosomal dominant inheritance, a
penetrance of 83%, and condition type 1 VTCP (93). Cases
of patients with VTCP due to pathogenic variants in the
CASQ2 gene that condition type 2 CPVT, represent only

5% of all cases. cases. They are inherited under an
autosomal recessive pattern (98), due to homozygous or
compound heterozygous pathogenic variants in the
CASQ2 gene and have a penetrance of 78% ( 9 9 ).
Alterations in other genes have also been identi ed
through genome-wide linkage analysis including the
calmodulin 1 (CALM1) genes in the origin of CPVT type 4
and the triadin gene (TRDN) as a cause. of type 5 CPVT
(100)
. Finally, SCN5A has been implicated in exerciseinduced polymorphic ventricular arrhythmias, with the
recent identi cation of a new missense mutation in a
highly conserved region of the gene in a large family
with a CPVT phenotype. CPVT should be suspected in all
young patients (mainly children/adolescents)
presenting with syncope related to physical exercise,
emotional stress, in the absence of structural heart
disease, and with an EKG without abnormalities (normal
QT interval) (93).
The diﬀerential diagnosis should be made with other
hereditary heart diseases that are susceptible to
producing malignant ventricular arrhythmias due to
exercise and/or emotional stress, such as long QT
syndrome (LQTS 1, LQTS 2 and LQTS 3), since both
conditions share clinical characteristics such as age
debut, absence of structural heart disease, family
history of syncope or sudden death, appearance of
symptoms related to physical or emotional stress and
the polymorphic nature of ventricular arrhythmias (93).
The biggest diﬀerence between both is the prolonged
QT interval in LQTS, although a normal QT interval does
not exclude the diagnosis of LQTS (5-10% of carriers of
genetic variants in LQTS show a normal QT interval).
Genetic testing is recommended as part of the
evaluation of an individual with exercise-induced or
polymorphic ventricular tachycardia (documented on
ECG), and when these arrhythmias occur in the setting
of emotional stress (100). They may also be considered in
the evaluation of cardiac arrest in the context of
exertion or emotional stress. RyR2 gene sequencing is
recommended in sporadic cases or when family history
suggests autosomal dominant inheritance (100). In
sporadic cases where there is a family history of
consanguinity or when an autosomal recessive
inheritance pattern is suspected, sequencing is
recommended. CASQ2 gene sequencing. Pathogenic
variants in the CASQ2 gene have been identi ed in only
1%-2% of all CPVT patients (100).
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CONCLUSIONS
The role of genetic studies in the risk strati cation of
sudden death is based on the study of the patient with
clinical suspicion of a cardiac disorder with genetic

available through multigene panels through nextgeneration sequencing (NGS), and in turn allow the
identi cation of new variants associated with the
disease, not all Patients have hospital access to these

origin. Genetic tests are useful for the diagnosis and

tests. One limitation of this review was not having a

clinical management of the patient, in addition, timely

national database on molecular studies of patients with

advice allows the identi cation of families at risk to

heart disease of genetic origin, this could be due to the

establish personalized follow-up and prevention

fact that they are not performed in any laboratory in the

measures, based on clinical guidelines and relevant

country, the cost of performing them abroad could not

scienti c information. Although technological

be covered by patients or that there have been no

advances currently allow us to have genetic studies

publications on this topic.
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